Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DBV Technologies S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHTILLON, FRANCE, JULY 30, 2026 DBV TECHNOLOGIES ANNOUNCES SALE OF APPROXIMATELY $50 MILLION OF ADSS THROUGH ITS AT-THE-MARKET (ATM) PROGRAM ON NASDAQ DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ CAPITAL MARKET: DBVT) (THE COMPANY), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT, PURSUANT TO THE COMPANY'S AT-THE-MARKET PROGRAM ESTABLISHED ON SEPTEMBER 1, 2025 AND INCLUDED IN A NEW REGISTRATION STATEMENT AND ACCOMPANYING PROSPECTUS FILED ON JULY 27, 2026, (THE ATM PROGRAM), IT HAS AGREED TO ISSUE AND SELL NEW ORDINARY SHARES (THE ORDINARY SHARES) IN THE FORM OF AMERICAN DEPOSITARY SHARES (ADSS), FOR TOTAL GROSS PROCEEDS TO THE COMPANY OF APPROXIMATELY $50 MILLION, BEFORE DEDUCTING SALES AGENT COMMISSIONS AND OFFERING EXPENSES PAYABLE BY THE COMPANY, TO RA CAPITAL MANAGEMENT, L.P (RA CAPITAL) THROUGH CITIZENS JMP SECURITIES, LLC (CITIZENS), ACTING AS SALES AGENT. EACH ADS REPRESENTS THE RIGHT TO RECEIVE FIVE ORDINARY SHARES OF THE COMPANY.

DBV TECHNOLOGIES ANNOUNCES SALE OF APPROXIMATELY $50 MILLION OF ADSS THROUGH ITS AT-THE-MARKET (ATM) PROGRAM ON NASDAQ

CHTILLON, FRANCE, JULY 17, 2026 DBV TECHNOLOGIES FILES AT-THE-MARKET (ATM) PROSPECTUS FOR UP TO $150 MILLION OF SALES DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ CAPITAL MARKET: DBVT) (THE COMPANY), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT HAS FILED A NEW AUTOMATICALLY EFFECTIVE SHELF REGISTRATION STATEMENT ON FORM S-3ASR (THE REGISTRATION STATEMENT) WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (SEC), WHICH INCLUDES A BASE PROSPECTUS AND A SALES AGREEMENT PROSPECTUS SUPPLEMENT REFRESHING THE COMPANY'S PREVIOUSLY ESTABLISHED AT-THE-MARKET OFFERING PROGRAM (THE ATM PROGRAM) BY FILING A PROSPECTUS SUPPLEMENT FOR SALES OF UP TO $150 MILLION OF AMERICAN DEPOSITARY SHARES (ADS). THE ATM PROGRAM WAS ESTABLISHED PURSUANT TO A SALES AGREEMENT DATED SEPTEMBER 5, 2025, (THE SALES AGREEMENT) WITH CITIZENS JMP SECURITIES, LLC (CITIZENS), ACTING AS SALES AGENT, UNDER WHICH THE COMPANY MAY OFFER AND SELL, FROM TIME TO TIME, ADSS, EACH ADS REPRESENTING FIVE ORDINARY SHARES OF THE COMPANY, HAVING AN AGGREGATE OFFERING PRICE OF UP TO $150 MILLION, SUBJECT TO FRENCH REGULATORY LIMITS.

DBV TECHNOLOGIES FILES AT-THE-MARKET (ATM) PROSPECTUS FOR UP TO $150 MILLION OF SALES

CHTILLON, FRANCE, JULY 16, 2026 DBV TE C HNOLOGIES ANNOUNCES THE FILING OF ITS 2026 HALF-YEAR REPORT  CONDITIONS FOR ACCESSING OR CONSULTING THE REPORT DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT), A LATE-STAGE BIOPHARMACEUTICAL COMPANY (THE COMPANY), TODAY ANNOUNCED THE FILING, FOR THE SEMESTER ENDED JUNE 30, 2026, OF ITS HALF-YEAR REPORT WITH THE FRENCH MARKET AUTHORITY, AUTORIT DES MARCHS FINANCIERS (AMF). THE 2026 HALF-YEAR REPORT CAN BE CONSULTED OR DOWNLOADED FROM THE COMPANY'S WEBSITE (WWW.DBV-TECHNOLOGIES.COM) IN THE SECTION INVESTORS/FINANCIAL INFORMATION, AND ON THE AMF WEBSITE (WWW.AMF-FRANCE.ORG), IN FRENCH ONLY.

DBV TECHNOLOGIES ANNOUNCES THE FILING OF ITS 2026 HALF-YEAR REPORT  CONDITIONS FOR ACCESSING OR CONSULTING THE REPORT

CHTILLON, FRANCE, JULY 16, 2026 DBV TECHNOLOGIES REPORTS SECOND QUARTER AND HALF-YEAR 2026 FINANCIAL RESULTS AND BUSINESS UPDATE CONTINUED PRODUCTIVE ENGAGEMENT WITH THE FDA IN SUPPORT OF THE BLA FOR THE VIASKIN PEANUT PATCH IN CHILDREN AGED 4 THROUGH 7 YEARS, WITH SUBMISSION OF THE BLA ANTICIPATED IN THE THIRD QUARTER OF 2026 REPORTED CASH AND CASH EQUIVALENTS OF $174.9 MILLION AS OF JUNE 30, 2026, FUNDING INTO THIRD QUARTER OF 2027 DBV WILL HOST A CONFERENCE CALL TODAY, JULY 16, AT 5:00PM ET DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT  CUSIP: 23306J309), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF-YEAR OF 2026. THE QUARTERLY AND HALF-YEAR FINANCIAL STATEMENTS WERE APPROVED BY THE BOARD OF DIRECTORS ON JULY 16, 2026.

DBV TECHNOLOGIES REPORTS SECOND QUARTER AND HALF-YEAR 2026 FINANCIAL RESULTS AND BUSINESS UPDATE

CHTILLON, FRANCE, JULY 14, 2026 DBV TECHNOLOGIES TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE ON JULY 16, 2026 COMPANY TO HOST INVESTOR CONFERENCE CALL AND WEBCAST AT 5:00 P.M. ET DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST ON THURSDAY, JULY 16TH, AT 5:00 P.M.

DBV TECHNOLOGIES TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE ON JULY 16, 2026

AMF REGULATED INFORMATION CHTILLON, FRANCE, JULY 6, 2026 HALF-YEAR REPORT ON THE DBV TECHNOLOGIES LIQUIDITY CONTRACT WITH ODDO BHF DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ISSUED THE HALF-YEAR REPORT ON ITS LIQUIDITY CONTRACT WITH ODDO BHF RELATING TO DBV TECHNOLOGIES SHARES (THE LIQUIDITY CONTRACT). THE LIQUIDITY CONTRACT IS IMPLEMENTED IN ACCORDANCE WITH AMF DECISION NO.

HALF-YEAR REPORT ON THE DBV TECHNOLOGIES LIQUIDITY CONTRACT WITH ODDO BHF

CHTILLON, FRANCE, JUNE 29, 2026 DBV TECHNOLOGIES PROVIDES BLA SUBMISSION UPDATE FOR THE VIASKIN PEANUT PATCH IN CHILDREN AGED 4 THROUGH 7 YEARS; WORKING COLLABORATIVELY WITH FDA TO OPTIMIZE REVIEW PROCESS IN PREPARATION FOR FILING DBV HAS BEEN ENGAGED IN EXTENSIVE DISCUSSIONS WITH THE FDA IN PREPARATION OF ITS BLA FOR THE VIASKIN PEANUT PATCH IN CHILDREN AGED FOUR THROUGH SEVEN YEARS THE OBJECTIVE OF THE DETAILED, ITERATIVE ENGAGEMENT WAS TO ENSURE A COMPLETE, EFFICIENT, AND TIMELY FDA REVIEW OF THE BLA, ONCE SUBMITTED THE AGENCY HAS NOT REQUESTED ADDITIONAL DATA DBV WILL TAKE ADDITIONAL TIME TO INCORPORATE THE FDA FEEDBACK AND ANTICIPATES SUBMITTING THE BLA IN THE THIRD QUARTER OF 2026 DBV WILL HOST A CONFERENCE CALL TODAY, JUNE 29, AT 5:00PM ET DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY PROVIDED AN UPDATE ON THE BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION SEEKING MARKETING APPROVAL OF THE VIASKIN PEANUT PATCH IN CHILDREN AGED FOUR THROUGH SEVEN YEARS. OVER RECENT WEEKS, DBV HAS HAD ONGOING DETAILED AND ITERATIVE ENGAGEMENT WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) WITH THE OBJECTIVE OF ENSURING A COMPLETE, EFFICIENT, AND TIMELY REVIEW OF THE COMPANY'S UPCOMING BLA FOR CHILDREN AGED FOUR THROUGH SEVEN YEARS.

DBV TECHNOLOGIES PROVIDES BLA SUBMISSION UPDATE FOR THE VIASKIN PEANUT PATCH IN CHILDREN AGED 4 THROUGH 7 YEARS; WORKING COLLABORATIVELY WITH FDA TO OPTIMIZE REVIEW PROCESS IN PREPARATION FOR FILING

CHTILLON, FRANCE, JUNE 23, 2026 DBV TECHNOLOGIES ANNOUNCES INCLUSION IN THE EURONEXT TECH LEADERS INDEX DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT  CUSIP: 23306J309), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY HAS BEEN INCLUDED IN THE EURONEXT TECH LEADERS INDEX. INCLUSION IN THE INDEX WENT INTO EFFECT ON JUNE 22, 2026.

DBV TECHNOLOGIES ANNOUNCES INCLUSION IN THE EURONEXT TECH LEADERS INDEX

CHTILLON, FRANCE, JUNE 9, 2026 DBV TECHNOLOGIES REVISES PARTICIPATION IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT) (THE COMPANY), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN 1-ON-1 INVESTOR MEETINGS AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, JUNE 9, 2026, IN MIAMI, FL. MR. DANIEL TASS, CEO, WILL NOT BE AVAILABLE FOR THE PREVIOUSLY SCHEDULED FIRESIDE CHAT DUE TO AN UNAVOIDABLE DISRUPTION OF PLANNED TRAVEL TO THE CONFERENCE.

DBV TECHNOLOGIES REVISES PARTICIPATION IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

CHTILLON, FRANCE, JUNE 8, 2026 DBV TECHNOLOGIES TO PRESENT NEW POSITIVE DATA FROM VITESSE STUDY AND PREVIEW RECENTLY INITIATED THRIVE STUDY AT THE EAACI CONGRESS 2026 IN THE PHASE 3 VITESSE STUDY, VIASKIN PEANUT PATCH DEMONSTRATED STATISTICALLY SIGNIFICANT EFFICACY VS. PLACEBO IN THE SUBGROUPS OF CHILDREN WITH PEANUT ALLERGY WHO ALSO HAD ANOTHER COMMON ATOPIC CONDITION, INCLUDING ASTHMA, CONCOMITANT FOOD ALLERGY, OR ATOPIC DERMATITIS.

DBV TECHNOLOGIES TO PRESENT NEW POSITIVE DATA FROM VITESSE STUDY AND PREVIEW RECENTLY INITIATED THRIVE STUDY AT THE EAACI CONGRESS 2026

CHTILLON, FRANCE, JUNE 5, 2026 DBV TECHNOLOGIES TO PARTICIPATE IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT) (THE COMPANY), A LATE-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT DANIEL TASS, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, JUNE 9, 2026, AT 9:20 AM ET, IN MIAMI, FL. A LIVE WEBCAST OF THE FIRESIDE CHAT CAN BE ACCESSEDHERE, AND WILL ALSO BE AVAILABLE ON THE EVENTS SECTION OF THE COMPANY'S INVESTORS WEBSITE:HTTPS://DBV-TECHNOLOGIES.COM/INVESTOR-OVERVIEW/EVENTS/, WITH AN ARCHIVED REPLAY ACCESSIBLE FOR 90 DAYS FOLLOWING THE EVENT.

DBV TECHNOLOGIES TO PARTICIPATE IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

CHTILLON, FRANCE, JUNE 3, 2026 DBV TECHNOLOGIES ANNOUNCES THE RESULTS OF ITS 2026 COMBINED GENERAL MEETING SHAREHOLDERS APPROVED ALL PROPOSED RESOLUTIONS DBV TECHNOLOGIES (EURONEXT: DBV  ISIN: FR0010417345  NASDAQ STOCK MARKET: DBVT), A LATE STAGE BIOPHARMACEUTICAL COMPANY (THE COMPANY), HELD ITS COMBINED GENERAL MEETING (THE GENERAL MEETING). THE GENERAL MEETING WAS CHAIRED BY MICHEL DE ROSEN, CHAIRMAN OF THE BOARD OF DIRECTORS (THE BOARD).

DBV Technologies S.A.

DBVT

Price

Financial Reports

No items found.

Press Releases

DBV Technologies S.A.

DBVT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

DBVT